Radiotherapy Devices Market

The global radiotherapy devices market continues to expand, with more than 13,000 systems—including linear accelerators, brachytherapy units, and proton therapy devices—deployed worldwide in 2024. Linear accelerators lead the market, driven by growing demand for precision, image-guided, and automated radiation treatments. North America and Europe dominate revenue due to advanced cancer care infrastructure and strong reimbursement frameworks, while Asia Pacific is rapidly growing as healthcare systems expand and cancer incidence rises. The market is shaped by advancements in IGRT, IMRT, proton therapy, AI-powered planning, and enhanced patient safety features, as hospitals prioritize accuracy, workflow efficiency, and personalized oncology care.

Global Market Snapshot

• In 2024, over 13,000 radiotherapy systems were deployed worldwide, including linear accelerators, brachytherapy units, and proton therapy devices.
• Linear accelerators dominate the radiotherapy devices market, accounting for 55% of revenue, followed by brachytherapy systems at 25% and proton therapy equipment at 15%.
• North America and Europe together contribute around 70% of total market revenue, highlighting high adoption in tertiary care hospitals and specialized cancer centers.
• The Asia Pacific radiotherapy devices market driven by expanding healthcare infrastructure, rising cancer prevalence, and government initiatives to improve oncology access.
• The market is increasingly focused on precision, automation, and patient safety, making radiotherapy devices a critical component of modern oncology treatment.

To know about the assumptions considered for the study download the pdf brochure

Regional Outlook

North America

• The U.S. leads adoption due to advanced hospital infrastructure, favorable reimbursement policies, and a high concentration of cancer centers.
• Hospitals prioritize image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic systems.
• The radiotherapy devices market in North America is highly competitive, with emphasis on innovation, workflow integration, and clinical outcomes.

Europe

• Germany, France, and the U.K. are key contributors, with strong growth in proton therapy and modern linear accelerator systems.
• Adoption is guided by regulatory standards (CE marking) and national radiation safety guidelines.
• Hospitals increasingly integrate multi-modality imaging and adaptive therapy for improved precision.

Asia Pacific

• Key countries: Japan, China, South Korea, India, and Australia.
• Growth is supported by government funding, expansion of private cancer care centers, and rising awareness of advanced oncology treatments.

Latin America

• Hospitals modernizing oncology infrastructure drive adoption of linear accelerators and brachytherapy systems.

Middle East & Africa

• Adoption concentrated in GCC countries, South Africa, and Egypt.
• Government initiatives and private oncology centers support the expansion of radiotherapy services.

Market Dynamics and Industry Signals

• Rising global cancer incidence and aging populations fuel demand for radiotherapy devices.
• Transition from conventional to image-guided and robotic-assisted radiotherapy drives equipment upgrades.
• Hospitals focus on precision, patient safety, and workflow efficiency.
• Regulatory compliance with FDA, CE, and local safety standards is critical for adoption.
• Market growth supported by private cancer care expansion and government healthcare investments.

Key Market Drivers

• Increasing prevalence of cancer and chronic illnesses globally.
• Adoption of advanced linear accelerators, proton therapy, and brachytherapy systems.
• Government funding and reimbursement policies promoting access to radiotherapy.
• Integration of AI and imaging technologies to improve treatment planning and outcomes.
• Expansion of healthcare infrastructure in emerging economies.

Technology Evolution

• Adoption of image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic radiotherapy.
• Emergence of proton and heavy-ion therapy systems for precise tumor targeting.
• Integration of AI-powered treatment planning and adaptive radiotherapy.
• Development of compact, cost-effective linear accelerators for smaller hospitals.
• Enhanced patient safety with automated beam control, motion management, and real-time monitoring.

Manufacturing and Production Expansion

• Major OEMs expanding production facilities to meet growing demand in APAC and North America.
• R&D investments focus on compact designs, automation, and workflow efficiency.
• Strategic collaborations with hospitals and research centers for product validation and clinical trials.
• Supply chain optimization for high-precision components, such as gantries, multileaf collimators, and imaging systems.
• Modular manufacturing enables scalable production based on regional demand.

Clinical Adoption and Buyer Considerations

• Hospitals prioritize equipment offering:
  • High precision and accuracy of treatment delivery
  • Patient safety and compliance with radiation standards
  • Integration with imaging modalities (CT, MRI, PET)
  • Ease of operation and workflow efficiency
• Buyer evaluation factors include:
  • Total cost of ownership, including maintenance and software upgrades
  • Staff training and operational support
  • Regulatory compliance (FDA, CE, national safety standards)
  • Vendor reputation and post-sale service quality
• Adoption is increasingly driven by improved patient outcomes, operational efficiency, and ability to deliver personalized radiotherapy.

Related Reports:

Radiotherapy Market by Technology (EBRT:MR LINAC, Stereotactic, Particle; IBRT/Brachytherapy, Cobalt-60 Teletherapy), Procedure (IGRT, IMRT, 3D-CRT, HDR, LDR, PDR), Cancer (Prostate, Breast, Lung, CRC), End User (Hospital, IRC) - Global Forecasts to 2030